Corvus Pharmaceuticals (CRVS)

• Market cap: $591M
• 1 day: 3.29%
• 5 days: 8.36%
• 1 month: 14.91%
• 3 months: 86.96%
• 6 months: 101.23%
• Year to date: 50.46%
• 1 year: -14.54%
• 5 years: 98.3%
• 10 years: -42.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31